ランレオチド酢酸塩
|
|
|
- CAS番號.
- 127984-74-1
- 化學(xué)名:
- ランレオチド酢酸塩
- 別名:
- ランレオチド アセタート;ランレオチド酢酸塩;ランレオチド酢酸塩 (JAN)
- 英語名:
- Lanreotide Acetate
- 英語別名:
- Somatulina;LANREOTIDE ACETATE;Angiopeptin acetate;Lanrui Peptide Acetate;Lanreotide Acetate(acetate);Lanreotide Acetate USP/EP/BP;10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)a...;3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide;10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- CBNumber:
- CB81260986
- 化學(xué)式:
- C54H69N11O10S2
- 分子量:
- 0
- MOL File:
- 127984-74-1.mol
- MSDS File:
- SDS
|
ランレオチド酢酸塩 物理性質(zhì)
- 融點 :
- >165°C (dec.)
- 貯蔵溫度 :
- -20°C
- 溶解性:
- DMSO（微量）、メタノール（微量）
- 外見 :
- 粉
- 色:
- ホワイトからオフホワイト
- InChIKey:
- PUDHBTGHUJUUFI-UHFFFAOYSA-N
- SMILES:
- S1CC(NC(=O)C(N)CC2=CC=C3C(=C2)C=CC=C3)C(=O)NC(CC2=CC=C(O)C=C2)C(=O)NC(CC2C3=C(NC=2)C=CC=C3)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(C(NC(C(=O)N)C(O)C)=O)CS1
安全性情報
- リスクと安全性に関する聲明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
區(qū)分 |
注意喚起語 |
シンボル |
P コード |
| H361 |
生殖能または胎児への悪影響のおそれの疑い |
生殖毒性 |
2 |
警告 |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| 注意書き |
|
ランレオチド酢酸塩 価格
もっと(2)
| メーカー |
製品番號 |
製品説明 |
CAS番號 |
包裝 |
価格 |
更新時間 |
購入 |
|
Sigma-Aldrich Japan
|
SML0132 |
ランレオチド アセタート ≥98% (HPLC)
Lanreotide acetate ≥98% (HPLC) |
127984-74-1 |
5mg |
￥32800 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML0132 |
ランレオチド アセタート ≥98% (HPLC)
Lanreotide acetate ≥98% (HPLC) |
127984-74-1 |
25mg |
￥78400 |
2024-03-01 |
購入 |
ランレオチド酢酸塩 化學(xué)特性,用途語,生産方法
効能
抗悪性腫瘍薬, ホルモン分泌抑制薬, ソマトスタチン受容體作動薬
商品名
ソマチュリン (帝人ファーマ)
説明
Lanreotide acetate, an octapeptide somatostatin analog, reached its first
worldwide market in France for acromegaly when surgery or radiotherapy have
failed to restore normal growth hormone secretion. Lanreotide is a selective inhibitor of
growth hormone and reduces the secretion of growth hormone, thyrotropin, motilin and
pancreatic polypeptide in humans. Lanreotide has antiproliferative properties and is
reportedly in clinical trials for the prevention of restenosis following coronary artery
angioplasty, for diabetic retinopathy, and as a therapy for psoriasis. Its potential for
neuroendocrine tumors and hormone-responsive prostate cancer has also been
demonstrated.
臨床応用
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007. Lanreotide acetate is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA) and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.). In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
ランレオチド酢酸塩 上流と下流の製品情報
原材料
準備製品
ランレオチド酢酸塩 生産企業(yè)
Global( 101)Suppliers
127984-74-1(ランレオチド酢酸塩)キーワード:
- 127984-74-1
- 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide
- Somatulina
- LANREOTIDE ACETATE
- 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate
- Angiopeptin acetate
- 10-(4-aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-19-[(2-amino-3-naphthalen-2-ylpropanoyl)amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
- Lanreotide Acetate USP/EP/BP
- 10-(4-aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)a...
- Lanreotide Acetate(acetate)
- Lanrui Peptide Acetate
- ランレオチド アセタート
- ランレオチド酢酸塩
- ランレオチド酢酸塩 (JAN)